<DOC>
	<DOCNO>NCT02322736</DOCNO>
	<brief_summary>The study shed additional light impact Vectibix® current , standard clinical condition mCRC treatment Greece . It provide data duration outcomes Vectibix® treatment real-life setting .</brief_summary>
	<brief_title>Prospective Observational Study 1st 2nd Line Vectibix® Use RAS-wt mCRC Pts Evaluate Pattern Use ORR</brief_title>
	<detailed_description>This single-arm , multi-center , prospective , observational , descriptive , noninterventional study patient mCRC Greece receive Vectibix®in 1st 2nd line accord approve indication . The aim study obtain clear understanding current practice concern real-life treatment mCRC patient Vectibix® first-line combination chemotherapy second-line combination chemotherapy Greece . This setting also provide opportunity observe non-selected patient population RAS WT mCRC real-life habit mCRC treatment , particular duration outcome Vectibix® treatment . The data generate study may use reimbursement purpose , become increasingly common need Greece provide locally generate data use drug real-life set regulatory agency and/or payors . Furthermore , study could address exist data gap treatment anti-EGFR therapy beyond progression real-life setting . Primary Objective ( ) : To describe pattern use Vectibix® combination chemotherapy 1st line 2nd line mCRC treatment per approve Vectibix® indication . Secondary Objective ( ) : To investigate rate objective response ( ORR , define either Complete Response Partial Response ) rate stable disease best response 1st line 2nd line chemotherapy regimen mCRC include Vectibix® .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Adult patient ( age ≥18 year ) enrollment Histological documentation mCRC diagnosis RAS WT tumor document study enrolment per routine laboratory find Subjects whose care manage primarily enrol physician and/or record available Measurable disease baseline ( preferably accord Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST v1.1 ) routinely use ) Currently ( begin 8 week informed consent ) 1st 2nd line treatment regimen , include Vectibix® per indication Tumor assessment ( i.e . CT/MRI ) within 16 week prior first Vectibix® infusion Signed informed consent Participation interventional clinical study ( currently three previous month enrollment ) . Compromised ability give inform consent ( define per clinical judgment ) . Unknown mutant RAS tumor type</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Metastatic Colorectal Cancer , wild type RAS , Panitumumab , Vectibix , Greece</keyword>
</DOC>